Descriptive Information

De.1. Measure Type *(Patient‐reported outcomes include HRQoL/functional status, symptom/burden, experience* *with care, health‐related behavior.)*\*

Process

[De.2. Measure Title *‐ Measure titles should be concise yet convey who and what is being measured (see* What](http://nqf.qualityforum.dev.win.dotnet.panth.com/docs/what_good_looks_like.aspx) [Good Looks Like*)*\*](http://nqf.qualityforum.dev.win.dotnet.panth.com/docs/what_good_looks_like.aspx)

Prescription of HIV Antiretroviral Therapy

De.3. Brief description of measure (*including type of score, measure focus, target population, timeframe, e.g.,* *Percentage of adult patients aged 18‐75 years receiving one or more HbA1c tests per year*)

Percentage of patients, regardless of age, with a diagnosis of HIV prescribed antiretroviral therapy for the treatment of HIV infection during the measurement year

De.4. IF PAIRED/GROUPED, what is the reason this measure must be reported with other measures to appropriately interpret results?

N/A

Measure Specifications

S.1. Measure‐specific Web Page *(Provide a URL link to a web page specific for this measure that contains current* *detailed specifications including code lists, risk model details, and supplemental materials. Do not enter a URL linking to a home page or to general information.)*

http://hab.hrsa.gov/clinical-quality-management/performance-measure-portfolio

S.2a. If this is an eMeasure, HQMF specifications must be attached. Attach the zipped output from the eMeasure authoring tool (MAT) ‐ if the MAT was not used, contact staff. (Use the specification fields in this online form for the plain‐language description of the specifications)

We will submit HIV viral suppression as both a chart abstracted measure and an e-measure. This form is for the chart abstracted measure.

S.2b. Data Dictionary, Code Table, or Value Sets *(and risk model codes and coefficients when applicable) must* *be attached. (Excel or csv file in the suggested format preferred ‐ if not, contact staff. Provide descriptors for any codes. Use one file with multiple worksheets as needed.)*

|  |  |  |  |
| --- | --- | --- | --- |
| **Variables Used** | **Variable Name Created** | **Logic** | **Notes** |
| Firstambulatorycaredate;  HIV(AIDS)diagnosisyear | step\_1 | case when month(firstambulatorycaredate) > 3   and &var = &year   and euci42 not in (select distinct euci42 from raw&year..rsrambul group by euci42 having min(datepart(servicedate)) <"01APR&YY"d )  then 0 else 1 end | This logic excludes individuals who are explicitly diagnosed during the measurement year and receive their first service with any provider after March. All others are included in the denominator. |
| servicecategoryid | core\_medical | max(case when servicecategoryid in (8,10,11,13,14,15,16,17,18,19) then 1 else 0 end) where euci42 corresponds to step\_1 == 1 | This is conditioning on receiving ANY OAMC service, not necessarily receiving an OAMC service from a specific provider |
| ART | haartrx | indicator in raw file, conditional on core\_medical = 1 | If a person ever has a viral load test during the year and has a core medical service then will be in this group |

S.3.1. For maintenance of endorsement: Are there changes to the specifications since the last updates/submission. If yes, update the specifications for S1‐2 and S4‐22 and explain reasons for the changes in S3.2.

No

S.3.2. For maintenance of endorsement, please briefly describe any important changes to the measure specifications since last measure update and explain the reasons. None

S.4. Numerator Statement *(Brief, narrative description of the measure focus or what is being measured about the* *target population, i.e., cases from the target population with the target process, condition, event, or outcome). DO NOT include the rationale for the measure.*

*IF an OUTCOME MEASURE, state the outcome being measured. Calculation of the risk‐adjusted outcome should be described in the calculation algorithm (S.14).*

Number of patients from the denominator prescribed HIV antiretroviral therapy during the measurement year.

S.5. Numerator Details *(All information required to identify and calculate the cases from the target population* *with the target process, condition, event, or outcome such as definitions, time period for data collection, specific data collection items/responses, code/value sets – Note: lists of individual codes with descriptors that exceed 1 page should be provided in an Excel or csv file in required format at S.2b)*

*IF an OUTCOME MEASURE, describe how the observed outcome is identified/counted. Calculation of the risk‐ adjusted outcome should be described in the calculation algorithm (S.14).*

Number of patients from the denominator prescribed HIV antiretroviral therapy during the measurement year.

S.6. Denominator Statement *(Brief, narrative description of the target population being measured)*

*IF an OUTCOME MEASURE, state the target population for the outcome. Calculation of the risk‐adjusted outcome should be described in the calculation algorithm (S.14).*

Number of patients, regardless of age, with a diagnosis of HIV with at least one medical visit in the measurement year

S.7. Denominator Details *(All information required to identify and calculate the target population/denominator* *such as definitions, time period for data collection, specific data collection items/responses, code/value sets – Note: lists of individual codes with descriptors that exceed 1 page should be provided in an Excel or csv file in required format at S.2b)*

*IF an OUTCOME MEASURE, describe how the target population is identified. Calculation of the risk‐adjusted outcome should be described in the calculation algorithm (S.14).*

To be included in the denominator, patients must meet all of the following conditions/events:

1. Patients of any age during the measurement year
2. Patients diagnosed with HIV during the first 3 months of the measurement year or prior to the measurement year
3. Patients who had at least one medical visit during the measurement year

S.8. Denominator Exclusions *(Brief narrative description of exclusions from the target population)*

There are no patient exclusions.

S.9. Denominator Exclusion Details

None

S.10. Stratification Information *N/A*

S.11. Risk Adjustment Type N/A

S.12. Type of score: Percentage

S.13. Interpretation of Score

Better quality is associated with a higher score.

S.14. Calculation Algorithm/Measure Logic

1. Identify the individuals who satisfy all specific criteria for inclusion in the denominator: 1.) diagnosed with HIV during the first 3 months of the measurement year or prior to the measurement year; and 2.) had at least one medical visit during the measurement year. The individuals who met these criteria are the denominator population.

2. Identify the individuals from the denominator population who meet the criterion for inclusion in the numerator: prescribed HIV antiretroviral therapy during the measurement year.

3. Calculate the percentage by dividing the numerator population by the denominator population and multiply by 100

Also illustrated in the diagram below.



S.15. Sampling

This measure does not sample.

S.16. Survey/Patient‐reported data

This measure is not based on a survey or instrument.

S.17. Data Source *(Check ONLY the sources for which the measure is SPECIFIED AND TESTED).* *If other, please describe in S.18.*

Paper Records: As previously stated, this measure will be submitted as a chart abstracted measure and an e-measure. This submission is for the chart abstracted measure.

S.18. Data Source or Collection Instrument

Electronic or paper records

S.19. Data Source or Collection Instrument

No data collection instrument provided

S.20. Level of Analysis *(Check ONLY the levels of analysis for which the measure is SPECIFIED AND TESTED)*

Facility

S.21. Care Setting *(Check ONLY the settings for which the measure is SPECIFIED AND TESTED)*

Clinician Office/Clinic

S.22. COMPOSITE Performance Measure ‐

This is not a composite measure.

Importance

Importance to Measure and Report is a threshold criterion that must be met in order to recommend a measure for endorsement. All three sub‐criteria must be met to pass this criterion. See guidance on evidence.

Evidence ([Measure evaluation criterion 1a](http://nqf.qualityforum.dev.win.dotnet.panth.com/#1a))

1a. Attach evidence submission form ([Click here to download Evidence Submission Form Template](http://nqf.qualityforum.dev.win.dotnet.panth.com/docs/NQF_evidence_attachment_FINAL_2016.aspx))

1a.1. For maintenance of endorsement:

Is there new evidence about the measure since the last update/submission?

Yes

Performance Gap ‐ Opportunity for Improvement ([Measure evaluation criterion 1b](http://nqf.qualityforum.dev.win.dotnet.panth.com/#1b))

1b.1. Briefly explain the rationale for this measure (e.g., how the measure will improve the quality of care, the benefits or improvements in quality envisioned by use of this measure)

Antiretroviral therapy (ART) reduces HIV-associated morbidity and mortality by maximally inhibiting HIV replication (as defined by achieving and maintaining plasma HIV RNA (viral load) below levels detectable by commercially available assays). Durable viral suppression improves immune function and quality of life, lowers the risk of both AIDS-defining and non-AIDS-defining complications, and prolongs life. Emerging evidence also suggests that additional benefits of ART-induced viral load suppression include a reduction in HIV-associated inflammation and possibly its associated complications.

Measures of viral replication are known to predict HIV disease progression. Among untreated HIV-infected individuals, time to clinical progression and mortality is fastest in those with greater viral loads (19). This finding is confirmed across the wide spectrum of HIV-infected patient populations such as injection drug users (IDUs), women, and individuals with hemophilia. Several studies have shown the prognostic value of pretherapy viral load for predicting post-therapy response. Once therapy has been initiated, failure to achieve viral suppression and viral load at the time of treatment failure are predictive of clinical disease progression.

ART has also been shown to reduce transmission of HIV. The risk of sexual HIV transmission is highly correlated with HIV viral load in the blood and genital secretions of the infected individual, and ART reduces HIV blood viral load as well as HIV viral shedding in potentially infectious body fluids including semen, cervicovaginal secretions, and anorectal secretions. A recent randomized controlled trial of sero-discordant heterosexual couples documented a 96% reduction in transmission from treated persons to their partners, and observational studies are consistent with these findings.

1b.2. Provide performance scores on the measure as specified (current and over time ) at the specified level of analysis. (This is required for maintenance of endorsement. Include mean, std dev, min, max, interquartile range, scores by decile. Describe the data source including number of measured entities; number of patients; dates of data; if a sample, characteristics of the entities include). This information also will be used to address the sub‐criterion on improvement (4b) under Usability and Use.

*Performance scores*

Provider-level performance scores for antiretroviral treatment (ART) for 2014 are presented below. Summary statistics (mean, std dev, min, max, interquartile range, scores by decile) for viral load suppression across all providers are presented separately. Data for years 2010-2013 are available upon request and were omitted due to space constraints.

Provider-level ART performance scores, 2014

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Site/provider ID | Total N | Patients w/ ≥1 medical visit during measurement year (n) | Number of patients prescribed ART (a) | % of patients prescribed ART (a/n) |
| **OVERALL** | 316,087 | 316,087 | 245,400 | **77.6%** |
| 55 | 417 | 417 | 232 | 55.6% |
| 63 | 24 | 24 | 22 | 91.7% |
| 82 | 93 | 93 | 15 | 16.1% |
| 88 | 1052 | 1052 | 933 | 88.7% |
| 96 | 613 | 613 | 431 | 70.3% |
| 101 | 140 | 140 | 64 | 45.7% |
| 105 | 145 | 145 | 91 | 62.8% |
| 112 | 196 | 196 | 180 | 91.8% |
| 113 | 248 | 248 | 241 | 97.2% |
| 117 | 1197 | 1197 | 1157 | 96.7% |
| 118 | 331 | 331 | 313 | 94.6% |
| 120 | 153 | 153 | 142 | 92.8% |
| 123 | 459 | 459 | 426 | 92.8% |
| 124 | 212 | 212 | 202 | 95.3% |
| 127 | 288 | 288 | 237 | 82.3% |
| 128 | 484 | 484 | 377 | 77.9% |
| 133 | 2437 | 2437 | 2188 | 89.8% |
| 135 | 140 | 140 | 130 | 92.9% |
| 138 | 44 | 44 | 38 | 86.4% |
| 140 | 11 | 11 | 11 | 100.0% |
| 141 | 216 | 216 | 127 | 58.8% |
| 143 | 124 | 124 | 95 | 76.6% |
| 144 | 337 | 337 | 298 | 88.4% |
| 147 | 139 | 139 | 115 | 82.7% |
| 148 | 49 | 49 | 45 | 91.8% |
| 149 | 115 | 115 | 103 | 89.6% |
| 154 | 588 | 588 | 562 | 95.6% |
| 155 | 23 | 23 | 23 | 100.0% |
| 156 | 46 | 46 | 46 | 100.0% |
| 158 | 134 | 134 | 95 | 70.9% |
| 159 | 218 | 218 | 187 | 85.8% |
| 160 | 90 | 90 | 88 | 97.8% |
| 164 | 71 | 71 | 58 | 81.7% |
| 168 | 766 | 766 | 749 | 97.8% |
| 169 | 144 | 144 | 139 | 96.5% |
| 170 | 259 | 259 | 252 | 97.3% |
| 171 | 280 | 280 | 127 | 45.4% |
| 172 | 289 | 289 | 283 | 97.9% |
| 173 | 154 | 154 | 108 | 70.1% |
| 174 | 346 | 346 | 335 | 96.8% |
| 175 | 157 | 157 | 141 | 89.8% |
| 176 | 1909 | 1909 | 1827 | 95.7% |
| 177 | 63 | 63 | 52 | 82.5% |
| 178 | 1541 | 1541 | 1237 | 80.3% |
| 179 | 81 | 81 | 74 | 91.4% |
| 181 | 518 | 518 | 490 | 94.6% |
| 182 | 919 | 919 | 450 | 49.0% |
| 183 | 478 | 478 | 443 | 92.7% |
| 184 | 369 | 369 | 356 | 96.5% |
| 186 | 101 | 101 | 101 | 100.0% |
| 187 | 404 | 404 | 390 | 96.5% |
| 188 | 471 | 471 | 471 | 100.0% |
| 191 | 364 | 364 | 338 | 92.9% |
| 192 | 560 | 560 | 171 | 30.5% |
| 194 | 228 | 228 | 202 | 88.6% |
| 196 | 1160 | 1160 | 1102 | 95.0% |
| 197 | 1145 | 1145 | 1054 | 92.1% |
| 199 | 514 | 514 | 448 | 87.2% |
| 201 | 3059 | 3059 | 2895 | 94.6% |
| 203 | 793 | 793 | 773 | 97.5% |
| 205 | 12 | 12 | 12 | 100.0% |
| 207 | 329 | 329 | 315 | 95.7% |
| 209 | 192 | 192 | 192 | 100.0% |
| 210 | 120 | 120 | 115 | 95.8% |
| 211 | 458 | 458 | 429 | 93.7% |
| 212 | 234 | 234 | 216 | 92.3% |
| 213 | 1312 | 1312 | 1225 | 93.4% |
| 214 | 694 | 694 | 674 | 97.1% |
| 215 | 347 | 347 | 343 | 98.9% |
| 216 | 495 | 495 | 460 | 92.9% |
| 217 | 247 | 247 | 240 | 97.2% |
| 220 | 298 | 298 | 283 | 95.0% |
| 221 | 186 | 186 | 173 | 93.0% |
| 222 | 351 | 351 | 25 | 7.1% |
| 223 | 1674 | 1674 | 64 | 3.8% |
| 224 | 534 | 534 | 517 | 96.8% |
| 225 | 1947 | 1947 | 1397 | 71.8% |
| 227 | 1004 | 1004 | 960 | 95.6% |
| 228 | 187 | 187 | 167 | 89.3% |
| 230 | 2241 | 2241 | 2150 | 95.9% |
| 231 | 652 | 652 | 527 | 80.8% |
| 232 | 230 | 230 | 197 | 85.7% |
| 233 | 1045 | 1045 | 994 | 95.1% |
| 235 | 144 | 144 | 134 | 93.1% |
| 236 | 353 | 353 | 292 | 82.7% |
| 238 | 1142 | 1142 | 1118 | 97.9% |
| 239 | 718 | 718 | 547 | 76.2% |
| 240 | 424 | 424 | 353 | 83.3% |
| 241 | 3020 | 3020 | 2677 | 88.6% |
| 242 | 177 | 177 | 164 | 92.7% |
| 244 | 439 | 439 | 429 | 97.7% |
| 245 | 670 | 670 | 612 | 91.3% |
| 246 | 1314 | 1314 | 1264 | 96.2% |
| 248 | 1805 | 1805 | 1525 | 84.5% |
| 252 | 315 | 315 | 305 | 96.8% |
| 253 | 851 | 851 | 819 | 96.2% |
| 255 | 98 | 98 | 46 | 46.9% |
| 256 | 311 | 311 | 279 | 89.7% |
| 257 | 492 | 492 | 485 | 98.6% |
| 259 | 111 | 111 | 61 | 55.0% |
| 263 | 606 | 606 | 10 | 1.7% |
| 265 | 2673 | 2673 | 2614 | 97.8% |
| 266 | 1053 | 1053 | 1014 | 96.3% |
| 267 | 1078 | 1078 | 6 | 0.6% |
| 268 | 321 | 321 | 64 | 19.9% |
| 269 | 467 | 467 | 450 | 96.4% |
| 271 | 72 | 72 | 70 | 97.2% |
| 273 | 1378 | 1378 | 1053 | 76.4% |
| 275 | 1061 | 1061 | 992 | 93.5% |
| 276 | 269 | 269 | 243 | 90.3% |
| 277 | 876 | 876 | 784 | 89.5% |
| 278 | 726 | 726 | 16 | 2.2% |
| 279 | 1101 | 1101 | 996 | 90.5% |
| 280 | 32 | 32 | 30 | 93.8% |
| 283 | 1124 | 1124 | 926 | 82.4% |
| 284 | 284 | 284 | 276 | 97.2% |
| 285 | 237 | 237 | 198 | 83.5% |
| 286 | 403 | 403 | 370 | 91.8% |
| 288 | 144 | 144 | 131 | 91.0% |
| 289 | 311 | 311 | 264 | 84.9% |
| 290 | 77 | 77 | 74 | 96.1% |
| 291 | 637 | 637 | 616 | 96.7% |
| 292 | 220 | 220 | 198 | 90.0% |
| 294 | 1324 | 1324 | 226 | 17.1% |
| 295 | 311 | 311 | 272 | 87.5% |
| 298 | 1414 | 1414 | 1228 | 86.9% |
| 299 | 679 | 679 | 24 | 3.5% |
| 302 | 748 | 748 | 678 | 90.6% |
| 303 | 297 | 297 | 297 | 100.0% |
| 304 | 753 | 753 | 715 | 95.0% |
| 305 | 1050 | 1050 | 1011 | 96.3% |
| 307 | 918 | 918 | 869 | 94.7% |
| 308 | 108 | 108 | 88 | 81.5% |
| 310 | 3009 | 3009 | 2823 | 93.8% |
| 311 | 208 | 208 | 192 | 92.3% |
| 312 | 93 | 93 | 86 | 92.5% |
| 313 | 151 | 151 | 142 | 94.0% |
| 314 | 1197 | 1197 | 1154 | 96.4% |
| 315 | 1015 | 1015 | 1001 | 98.6% |
| 316 | 241 | 241 | 215 | 89.2% |
| 317 | 209 | 209 | 198 | 94.7% |
| 318 | 451 | 451 | 378 | 83.8% |
| 319 | 130 | 130 | 126 | 96.9% |
| 320 | 161 | 161 | 157 | 97.5% |
| 321 | 138 | 138 | 127 | 92.0% |
| 322 | 163 | 163 | 149 | 91.4% |
| 323 | 355 | 355 | 281 | 79.2% |
| 324 | 226 | 226 | 220 | 97.4% |
| 325 | 1815 | 1815 | 1439 | 79.3% |
| 326 | 722 | 722 | 708 | 98.1% |
| 328 | 556 | 556 | 8 | 1.4% |
| 329 | 5790 | 5790 | 5604 | 96.8% |
| 332 | 443 | 443 | 441 | 99.6% |
| 333 | 98 | 98 | 92 | 93.9% |
| 334 | 320 | 320 | 310 | 96.9% |
| 335 | 527 | 527 | 496 | 94.1% |
| 336 | 445 | 445 | 393 | 88.3% |
| 340 | 293 | 293 | 277 | 94.5% |
| 342 | 380 | 380 | 371 | 97.6% |
| 343 | 227 | 227 | 221 | 97.4% |
| 344 | 634 | 634 | 273 | 43.1% |
| 345 | 120 | 120 | 114 | 95.0% |
| 347 | 1048 | 1048 | 942 | 89.9% |
| 348 | 319 | 319 | 308 | 96.6% |
| 349 | 318 | 318 | 290 | 91.2% |
| 351 | 587 | 587 | 565 | 96.3% |
| 353 | 650 | 650 | 347 | 53.4% |
| 357 | 1141 | 1141 | 1075 | 94.2% |
| 358 | 142 | 142 | 137 | 96.5% |
| 360 | 772 | 772 | 724 | 93.8% |
| 361 | 598 | 598 | 551 | 92.1% |
| 362 | 69 | 69 | 67 | 97.1% |
| 363 | 118 | 118 | 111 | 94.1% |
| 365 | 42 | 42 | 37 | 88.1% |
| 366 | 177 | 177 | 161 | 91.0% |
| 368 | 344 | 344 | 326 | 94.8% |
| 369 | 234 | 234 | 232 | 99.2% |
| 370 | 89 | 89 | 77 | 86.5% |
| 371 | 104 | 104 | 103 | 99.0% |
| 372 | 1125 | 1125 | 1009 | 89.7% |
| 375 | 1789 | 1789 | 1346 | 75.2% |
| 378 | 65 | 65 | 60 | 92.3% |
| 379 | 1111 | 1111 | 1093 | 98.4% |
| 380 | 489 | 489 | 412 | 84.3% |
| 382 | 675 | 675 | 663 | 98.2% |
| 384 | 277 | 277 | 240 | 86.6% |
| 385 | 209 | 209 | 201 | 96.2% |
| 386 | 178 | 178 | 170 | 95.5% |
| 388 | 1342 | 1342 | 1275 | 95.0% |
| 389 | 206 | 206 | 167 | 81.1% |
| 390 | 362 | 362 | 328 | 90.6% |
| 391 | 220 | 220 | 192 | 87.3% |
| 393 | 758 | 758 | 728 | 96.0% |
| 394 | 64 | 64 | 49 | 76.6% |
| 395 | 709 | 709 | 683 | 96.3% |
| 400 | 235 | 235 | 225 | 95.7% |
| 404 | 154 | 154 | 141 | 91.6% |
| 407 | 369 | 369 | 65 | 17.6% |
| 408 | 617 | 617 | 589 | 95.5% |
| 409 | 126 | 126 | 121 | 96.0% |
| 410 | 80 | 80 | 30 | 37.5% |
| 412 | 463 | 463 | 423 | 91.4% |
| 414 | 130 | 130 | 127 | 97.7% |
| 417 | 112 | 112 | 69 | 61.6% |
| 421 | 644 | 644 | 572 | 88.8% |
| 422 | 410 | 410 | 396 | 96.6% |
| 423 | 384 | 384 | 30 | 7.8% |
| 425 | 235 | 235 | 221 | 94.0% |
| 427 | 1613 | 1613 | 1442 | 89.4% |
| 438 | 551 | 551 | 513 | 93.1% |
| 441 | 76 | 76 | 67 | 88.2% |
| 457 | 1186 | 1186 | 1151 | 97.1% |
| 463 | 343 | 343 | 282 | 82.2% |
| 469 | 379 | 379 | 317 | 83.6% |
| 473 | 1 | 1 | 0 | 0.0% |
| 480 | 362 | 362 | 288 | 79.6% |
| 481 | 292 | 292 | 276 | 94.5% |
| 483 | 879 | 879 | 735 | 83.6% |
| 489 | 748 | 748 | 548 | 73.3% |
| 491 | 89 | 89 | 4 | 4.5% |
| 498 | 550 | 550 | 533 | 96.9% |
| 504 | 1566 | 1566 | 1502 | 95.9% |
| 506 | 312 | 312 | 302 | 96.8% |
| 509 | 751 | 751 | 715 | 95.2% |
| 510 | 124 | 124 | 115 | 92.7% |
| 517 | 317 | 317 | 257 | 81.1% |
| 534 | 504 | 504 | 495 | 98.2% |
| 553 | 23 | 23 | 15 | 65.2% |
| 593 | 122 | 122 | 117 | 95.9% |
| 598 | 244 | 244 | 215 | 88.1% |
| 612 | 90 | 90 | 88 | 97.8% |
| 664 | 321 | 321 | 312 | 97.2% |
| 704 | 210 | 210 | 208 | 99.1% |
| 710 | 51 | 51 | 43 | 84.3% |
| 726 | 297 | 297 | 245 | 82.5% |
| 738 | 18 | 18 | 13 | 72.2% |
| 744 | 403 | 403 | 368 | 91.3% |
| 753 | 302 | 302 | 227 | 75.2% |
| 757 | 133 | 133 | 130 | 97.7% |
| 762 | 640 | 640 | 539 | 84.2% |
| 765 | 251 | 251 | 239 | 95.2% |
| 775 | 106 | 106 | 84 | 79.3% |
| 783 | 45 | 45 | 33 | 73.3% |
| 787 | 153 | 153 | 149 | 97.4% |
| 791 | 332 | 332 | 324 | 97.6% |
| 793 | 21 | 21 | 19 | 90.5% |
| 794 | 66 | 66 | 46 | 69.7% |
| 798 | 761 | 761 | 366 | 48.1% |
| 799 | 54 | 54 | 52 | 96.3% |
| 800 | 188 | 188 | 177 | 94.2% |
| 801 | 30 | 30 | 30 | 100.0% |
| 803 | 364 | 364 | 312 | 85.7% |
| 807 | 234 | 234 | 228 | 97.4% |
| 818 | 1336 | 1336 | 1325 | 99.2% |
| 820 | 94 | 94 | 85 | 90.4% |
| 821 | 82 | 82 | 81 | 98.8% |
| 824 | 44 | 44 | 42 | 95.5% |
| 841 | 93 | 93 | 92 | 98.9% |
| 852 | 139 | 139 | 139 | 100.0% |
| 861 | 230 | 230 | 230 | 100.0% |
| 867 | 930 | 930 | 473 | 50.9% |
| 871 | 1205 | 1205 | 927 | 76.9% |
| 873 | 278 | 278 | 227 | 81.7% |
| 894 | 2020 | 2020 | 1801 | 89.2% |
| 905 | 853 | 853 | 419 | 49.1% |
| 907 | 2792 | 2792 | 2034 | 72.9% |
| 913 | 1313 | 1313 | 204 | 15.5% |
| 920 | 15 | 15 | 3 | 20.0% |
| 926 | 37 | 37 | 30 | 81.1% |
| 927 | 113 | 113 | 3 | 2.7% |
| 929 | 140 | 140 | 83 | 59.3% |
| 933 | 204 | 204 | 18 | 8.8% |
| 945 | 121 | 121 | 115 | 95.0% |
| 980 | 142 | 142 | 122 | 85.9% |
| 986 | 141 | 141 | 124 | 87.9% |
| 992 | 1356 | 1356 | 1280 | 94.4% |
| 996 | 905 | 905 | 698 | 77.1% |
| 1009 | 153 | 153 | 95 | 62.1% |
| 1017 | 94 | 94 | 92 | 97.9% |
| 1022 | 242 | 242 | 234 | 96.7% |
| 1023 | 195 | 195 | 141 | 72.3% |
| 1026 | 105 | 105 | 102 | 97.1% |
| 1029 | 159 | 159 | 121 | 76.1% |
| 1031 | 543 | 543 | 508 | 93.6% |
| 1036 | 382 | 382 | 378 | 99.0% |
| 1037 | 104 | 104 | 103 | 99.0% |
| 1038 | 316 | 316 | 289 | 91.5% |
| 1049 | 434 | 434 | 378 | 87.1% |
| 1050 | 833 | 833 | 810 | 97.2% |
| 1052 | 27 | 27 | 23 | 85.2% |
| 1055 | 341 | 341 | 267 | 78.3% |
| 1056 | 758 | 758 | 719 | 94.9% |
| 1066 | 573 | 573 | 538 | 93.9% |
| 1067 | 671 | 671 | 565 | 84.2% |
| 1068 | 1485 | 1485 | 1078 | 72.6% |
| 1093 | 69 | 69 | 54 | 78.3% |
| 1094 | 778 | 778 | 620 | 79.7% |
| 1100 | 556 | 556 | 530 | 95.3% |
| 1109 | 1047 | 1047 | 1015 | 96.9% |
| 1110 | 120 | 120 | 116 | 96.7% |
| 1112 | 1712 | 1712 | 1666 | 97.3% |
| 1120 | 810 | 810 | 539 | 66.5% |
| 1121 | 1665 | 1665 | 1604 | 96.3% |
| 1122 | 411 | 411 | 372 | 90.5% |
| 1131 | 1024 | 1024 | 932 | 91.0% |
| 1132 | 186 | 186 | 125 | 67.2% |
| 1146 | 15 | 15 | 8 | 53.3% |
| 1155 | 436 | 436 | 414 | 95.0% |
| 1160 | 1383 | 1383 | 31 | 2.2% |
| 1162 | 54 | 54 | 1 | 1.9% |
| 1163 | 303 | 303 | 6 | 2.0% |
| 1167 | 2834 | 2834 | 2569 | 90.7% |
| 1214 | 147 | 147 | 144 | 98.0% |
| 1216 | 108 | 108 | 92 | 85.2% |
| 1229 | 276 | 276 | 268 | 97.1% |
| 1230 | 146 | 146 | 96 | 65.8% |
| 1263 | 1 | 1 | 1 | 100.0% |
| 1276 | 322 | 322 | 254 | 78.9% |
| 1278 | 103 | 103 | 82 | 79.6% |
| 1284 | 98 | 98 | 98 | 100.0% |
| 1287 | 873 | 873 | 838 | 96.0% |
| 1289 | 38 | 38 | 36 | 94.7% |
| 1300 | 62 | 62 | 27 | 43.6% |
| 1302 | 333 | 333 | 291 | 87.4% |
| 1309 | 72 | 72 | 47 | 65.3% |
| 1310 | 56 | 56 | 54 | 96.4% |
| 1314 | 539 | 539 | 450 | 83.5% |
| 1318 | 73 | 73 | 52 | 71.2% |
| 1319 | 95 | 95 | 82 | 86.3% |
| 1333 | 281 | 281 | 60 | 21.4% |
| 1349 | 57 | 57 | 1 | 1.8% |
| 1358 | 175 | 175 | 81 | 46.3% |
| 1359 | 2177 | 2177 | 1944 | 89.3% |
| 1364 | 73 | 73 | 65 | 89.0% |
| 1378 | 141 | 141 | 140 | 99.3% |
| 1380 | 78 | 78 | 69 | 88.5% |
| 1382 | 137 | 137 | 93 | 67.9% |
| 1401 | 604 | 604 | 385 | 63.7% |
| 1430 | 53 | 53 | 25 | 47.2% |
| 1444 | 37 | 37 | 26 | 70.3% |
| 1445 | 1601 | 1601 | 1319 | 82.4% |
| 1448 | 21 | 21 | 11 | 52.4% |
| 1451 | 94 | 94 | 88 | 93.6% |
| 1456 | 1635 | 1635 | 655 | 40.1% |
| 1461 | 127 | 127 | 123 | 96.9% |
| 1464 | 275 | 275 | 156 | 56.7% |
| 1479 | 12 | 12 | 11 | 91.7% |
| 1490 | 40 | 40 | 37 | 92.5% |
| 1511 | 647 | 647 | 608 | 94.0% |
| 1512 | 181 | 181 | 150 | 82.9% |
| 1514 | 43 | 43 | 11 | 25.6% |
| 1527 | 20 | 20 | 15 | 75.0% |
| 1552 | 1709 | 1709 | 1592 | 93.2% |
| 1567 | 90 | 90 | 88 | 97.8% |
| 1570 | 153 | 153 | 141 | 92.2% |
| 1572 | 51 | 51 | 42 | 82.4% |
| 1574 | 96 | 96 | 88 | 91.7% |
| 1582 | 161 | 161 | 146 | 90.7% |
| 1583 | 4 | 4 | 4 | 100.0% |
| 1587 | 12 | 12 | 10 | 83.3% |
| 1594 | 59 | 59 | 45 | 76.3% |
| 1597 | 27 | 27 | 11 | 40.7% |
| 1607 | 232 | 232 | 204 | 87.9% |
| 1610 | 216 | 216 | 192 | 88.9% |
| 1628 | 32 | 32 | 9 | 28.1% |
| 1634 | 104 | 104 | 92 | 88.5% |
| 1635 | 110 | 110 | 100 | 90.9% |
| 1637 | 309 | 309 | 277 | 89.6% |
| 1650 | 126 | 126 | 121 | 96.0% |
| 1654 | 52 | 52 | 42 | 80.8% |
| 1656 | 132 | 132 | 130 | 98.5% |
| 1668 | 986 | 986 | 921 | 93.4% |
| 1672 | 27 | 27 | 27 | 100.0% |
| 1684 | 1708 | 1708 | 1214 | 71.1% |
| 1719 | 1213 | 1213 | 1024 | 84.4% |
| 1762 | 945 | 945 | 12 | 1.3% |
| 1784 | 156 | 156 | 149 | 95.5% |
| 1786 | 66 | 66 | 37 | 56.1% |
| 1792 | 840 | 840 | 628 | 74.8% |
| 1806 | 9 | 9 | 0 | 0.0% |
| 1809 | 739 | 739 | 5 | 0.7% |
| 1812 | 731 | 731 | 9 | 1.2% |
| 1831 | 75 | 75 | 75 | 100.0% |
| 1834 | 42 | 42 | 40 | 95.2% |
| 1847 | 98 | 98 | 94 | 95.9% |
| 1849 | 144 | 144 | 126 | 87.5% |
| 1879 | 191 | 191 | 95 | 49.7% |
| 1900 | 1 | 1 | 0 | 0.0% |
| 1904 | 28 | 28 | 26 | 92.9% |
| 1912 | 635 | 635 | 603 | 95.0% |
| 1930 | 110 | 110 | 102 | 92.7% |
| 1955 | 116 | 116 | 90 | 77.6% |
| 1967 | 33 | 33 | 11 | 33.3% |
| 1968 | 32 | 32 | 14 | 43.8% |
| 1970 | 8 | 8 | 0 | 0.0% |
| 1972 | 2 | 2 | 0 | 0.0% |
| 1977 | 27 | 27 | 16 | 59.3% |
| 1980 | 49 | 49 | 47 | 95.9% |
| 1989 | 108 | 108 | 94 | 87.0% |
| 2003 | 4 | 4 | 2 | 50.0% |
| 2008 | 6 | 6 | 5 | 83.3% |
| 2010 | 10 | 10 | 9 | 90.0% |
| 2011 | 21 | 21 | 19 | 90.5% |
| 2017 | 33 | 33 | 33 | 100.0% |
| 2020 | 10 | 10 | 5 | 50.0% |
| 2025 | 268 | 268 | 243 | 90.7% |
| 2028 | 194 | 194 | 167 | 86.1% |
| 2029 | 88 | 88 | 80 | 90.9% |
| 2034 | 53 | 53 | 50 | 94.3% |
| 2041 | 8 | 8 | 0 | 0.0% |
| 2049 | 41 | 41 | 32 | 78.1% |
| 2058 | 291 | 291 | 278 | 95.5% |
| 2072 | 33 | 33 | 33 | 100.0% |
| 2073 | 740 | 740 | 706 | 95.4% |
| 2076 | 23 | 23 | 19 | 82.6% |
| 2078 | 32 | 32 | 30 | 93.8% |
| 2080 | 3 | 3 | 3 | 100.0% |
| 2081 | 2 | 2 | 1 | 50.0% |
| 2116 | 109 | 109 | 77 | 70.6% |
| 2117 | 23 | 23 | 19 | 82.6% |
| 2118 | 93 | 93 | 67 | 72.0% |
| 2126 | 135 | 135 | 120 | 88.9% |
| 2127 | 90 | 90 | 82 | 91.1% |
| 2129 | 140 | 140 | 97 | 69.3% |
| 2133 | 356 | 356 | 282 | 79.2% |
| 2134 | 31 | 31 | 29 | 93.6% |
| 2137 | 26 | 26 | 26 | 100.0% |
| 2139 | 163 | 163 | 75 | 46.0% |
| 2141 | 348 | 348 | 277 | 79.6% |
| 2143 | 996 | 996 | 928 | 93.2% |
| 2148 | 124 | 124 | 89 | 71.8% |
| 2150 | 1341 | 1341 | 1239 | 92.4% |
| 2153 | 158 | 158 | 123 | 77.9% |
| 2163 | 205 | 205 | 103 | 50.2% |
| 2170 | 318 | 318 | 230 | 72.3% |
| 2174 | 5229 | 5229 | 3195 | 61.1% |
| 2175 | 191 | 191 | 178 | 93.2% |
| 2178 | 407 | 407 | 345 | 84.8% |
| 2180 | 974 | 974 | 930 | 95.5% |
| 2183 | 175 | 175 | 154 | 88.0% |
| 2187 | 24 | 24 | 23 | 95.8% |
| 2188 | 19 | 19 | 15 | 79.0% |
| 2189 | 21 | 21 | 20 | 95.2% |
| 2191 | 62 | 62 | 60 | 96.8% |
| 2198 | 49 | 49 | 49 | 100.0% |
| 2200 | 33 | 33 | 30 | 90.9% |
| 2203 | 109 | 109 | 96 | 88.1% |
| 2205 | 53 | 53 | 49 | 92.5% |
| 2207 | 2326 | 2326 | 1787 | 76.8% |
| 2224 | 714 | 714 | 702 | 98.3% |
| 2228 | 19 | 19 | 9 | 47.4% |
| 2230 | 113 | 113 | 23 | 20.4% |
| 2232 | 5 | 5 | 1 | 20.0% |
| 2246 | 233 | 233 | 141 | 60.5% |
| 2252 | 64 | 64 | 18 | 28.1% |
| 2263 | 25 | 25 | 23 | 92.0% |
| 2264 | 2 | 2 | 1 | 50.0% |
| 2296 | 301 | 301 | 294 | 97.7% |
| 2299 | 548 | 548 | 38 | 6.9% |
| 2320 | 967 | 967 | 852 | 88.1% |
| 2366 | 70 | 70 | 47 | 67.1% |
| 2368 | 68 | 68 | 30 | 44.1% |
| 2374 | 2 | 2 | 0 | 0.0% |
| 2378 | 19 | 19 | 16 | 84.2% |
| 2379 | 23 | 23 | 14 | 60.9% |
| 2381 | 155 | 155 | 133 | 85.8% |
| 2388 | 6 | 6 | 4 | 66.7% |
| 2389 | 1 | 1 | 1 | 100.0% |
| 2415 | 129 | 129 | 126 | 97.7% |
| 2420 | 124 | 124 | 60 | 48.4% |
| 2436 | 181 | 181 | 178 | 98.3% |
| 2438 | 59 | 59 | 58 | 98.3% |
| 2444 | 2 | 2 | 0 | 0.0% |
| 2457 | 224 | 224 | 218 | 97.3% |
| 2474 | 263 | 263 | 213 | 81.0% |
| 2495 | 67 | 67 | 60 | 89.6% |
| 2514 | 13850 | 13850 | 4303 | 31.1% |
| 2525 | 765 | 765 | 739 | 96.6% |
| 2572 | 634 | 634 | 273 | 43.1% |
| 2654 | 38 | 38 | 18 | 47.4% |
| 2694 | 1 | 1 | 0 | 0.0% |
| 2699 | 19 | 19 | 18 | 94.7% |
| 2700 | 441 | 441 | 413 | 93.7% |
| 2702 | 428 | 428 | 402 | 93.9% |
| 2703 | 493 | 493 | 467 | 94.7% |
| 2704 | 340 | 340 | 317 | 93.2% |
| 2707 | 1 | 1 | 1 | 100.0% |
| 2709 | 1052 | 1052 | 996 | 94.7% |
| 2714 | 254 | 254 | 249 | 98.0% |
| 2717 | 125 | 125 | 110 | 88.0% |
| 2718 | 1952 | 1952 | 1886 | 96.6% |
| 2720 | 126 | 126 | 117 | 92.9% |
| 2721 | 1119 | 1119 | 1002 | 89.5% |
| 2723 | 347 | 347 | 332 | 95.7% |
| 2728 | 264 | 264 | 143 | 54.2% |
| 2732 | 434 | 434 | 408 | 94.0% |
| 2737 | 43 | 43 | 35 | 81.4% |
| 2745 | 120 | 120 | 118 | 98.3% |
| 2746 | 126 | 126 | 62 | 49.2% |
| 2757 | 225 | 225 | 200 | 88.9% |
| 2764 | 187 | 187 | 1 | 0.5% |
| 2766 | 156 | 156 | 0 | 0.0% |
| 2767 | 42 | 42 | 2 | 4.8% |
| 2768 | 1680 | 1680 | 25 | 1.5% |
| 2769 | 63 | 63 | 60 | 95.2% |
| 2771 | 339 | 339 | 4 | 1.2% |
| 2775 | 766 | 766 | 8 | 1.0% |
| 2779 | 226 | 226 | 2 | 0.9% |
| 2782 | 189 | 189 | 5 | 2.7% |
| 2788 | 207 | 207 | 2 | 1.0% |
| 2790 | 488 | 488 | 6 | 1.2% |
| 2794 | 52 | 52 | 3 | 5.8% |
| 2795 | 134 | 134 | 0 | 0.0% |
| 2849 | 383 | 383 | 324 | 84.6% |
| 2855 | 131 | 131 | 119 | 90.8% |
| 2856 | 55 | 55 | 48 | 87.3% |
| 2857 | 22 | 22 | 22 | 100.0% |
| 2865 | 556 | 556 | 369 | 66.4% |
| 2872 | 41 | 41 | 37 | 90.2% |
| 2873 | 7 | 7 | 5 | 71.4% |
| 2892 | 273 | 273 | 228 | 83.5% |
| 2893 | 266 | 266 | 251 | 94.4% |
| 2928 | 491 | 491 | 429 | 87.4% |
| 2929 | 85 | 85 | 33 | 38.8% |
| 2933 | 177 | 177 | 157 | 88.7% |
| 2945 | 210 | 210 | 195 | 92.9% |
| 2947 | 808 | 808 | 606 | 75.0% |
| 2948 | 471 | 471 | 446 | 94.7% |
| 2949 | 162 | 162 | 119 | 73.5% |
| 2951 | 205 | 205 | 168 | 82.0% |
| 2958 | 36 | 36 | 34 | 94.4% |
| 2959 | 52 | 52 | 43 | 82.7% |
| 2966 | 120 | 120 | 108 | 90.0% |
| 2969 | 70 | 70 | 61 | 87.1% |
| 2970 | 100 | 100 | 98 | 98.0% |
| 2988 | 93 | 93 | 64 | 68.8% |
| 2989 | 9 | 9 | 9 | 100.0% |
| 2997 | 896 | 896 | 865 | 96.5% |
| 3010 | 347 | 347 | 329 | 94.8% |
| 3012 | 183 | 183 | 160 | 87.4% |
| 3020 | 4 | 4 | 0 | 0.0% |
| 3048 | 19 | 19 | 7 | 36.8% |
| 3052 | 135 | 135 | 0 | 0.0% |
| 3077 | 79 | 79 | 78 | 98.7% |
| 3079 | 134 | 134 | 130 | 97.0% |
| 3111 | 71 | 71 | 46 | 64.8% |
| 3131 | 212 | 212 | 180 | 84.9% |
| 3133 | 89 | 89 | 70 | 78.7% |
| 3164 | 50 | 50 | 48 | 96.0% |
| 3177 | 165 | 165 | 141 | 85.5% |
| 3187 | 73 | 73 | 45 | 61.6% |
| 3210 | 315 | 315 | 299 | 94.9% |
| 3255 | 75 | 75 | 69 | 92.0% |
| 3261 | 151 | 151 | 145 | 96.0% |
| 3262 | 44 | 44 | 39 | 88.6% |
| 3264 | 29 | 29 | 28 | 96.6% |
| 3265 | 177 | 177 | 168 | 94.9% |
| 3310 | 197 | 197 | 187 | 94.9% |
| 3359 | 125 | 125 | 95 | 76.0% |
| 3389 | 33 | 33 | 33 | 100.0% |
| 3397 | 235 | 235 | 76 | 32.3% |
| 3401 | 112 | 112 | 41 | 36.6% |
| 3428 | 459 | 459 | 453 | 98.7% |
| 3433 | 205 | 205 | 134 | 65.4% |
| 3440 | 266 | 266 | 254 | 95.5% |
| 3444 | 213 | 213 | 173 | 81.2% |
| 3445 | 56 | 56 | 50 | 89.3% |
| 3449 | 44 | 44 | 44 | 100.0% |
| 3456 | 348 | 348 | 246 | 70.7% |
| 3469 | 263 | 263 | 258 | 98.1% |
| 3482 | 108 | 108 | 102 | 94.4% |
| 3484 | 334 | 334 | 326 | 97.6% |
| 3498 | 20 | 20 | 18 | 90.0% |
| 3507 | 55 | 55 | 53 | 96.4% |
| 3519 | 355 | 355 | 330 | 93.0% |
| 3521 | 80 | 80 | 80 | 100.0% |
| 3523 | 124 | 124 | 118 | 95.2% |
| 3527 | 256 | 256 | 240 | 93.8% |
| 3530 | 197 | 197 | 2 | 1.0% |
| 3533 | 9 | 9 | 9 | 100.0% |
| 3538 | 110 | 110 | 108 | 98.2% |
| 3551 | 313 | 313 | 237 | 75.7% |
| 3552 | 23 | 23 | 7 | 30.4% |
| 3553 | 53 | 53 | 48 | 90.6% |
| 3554 | 27 | 27 | 12 | 44.4% |
| 3573 | 146 | 146 | 145 | 99.3% |
| 3579 | 143 | 143 | 143 | 100.0% |
| 3583 | 1125 | 1125 | 1124 | 99.9% |
| 3587 | 80 | 80 | 73 | 91.3% |
| 3591 | 38 | 38 | 33 | 86.8% |
| 3593 | 241 | 241 | 111 | 46.1% |
| 3594 | 127 | 127 | 109 | 85.8% |
| 3595 | 792 | 792 | 667 | 84.2% |
| 3596 | 110 | 110 | 104 | 94.6% |
| 3597 | 257 | 257 | 253 | 98.4% |
| 3598 | 71 | 71 | 67 | 94.4% |
| 3600 | 40 | 40 | 31 | 77.5% |
| 3601 | 747 | 747 | 720 | 96.4% |
| 3602 | 91 | 91 | 74 | 81.3% |
| 3603 | 125 | 125 | 121 | 96.8% |
| 3604 | 12 | 12 | 12 | 100.0% |
| 3605 | 146 | 146 | 130 | 89.0% |
| 3606 | 194 | 194 | 174 | 89.7% |
| 3607 | 559 | 559 | 530 | 94.8% |
| 3608 | 236 | 236 | 208 | 88.1% |
| 3609 | 50 | 50 | 46 | 92.0% |
| 3625 | 68 | 68 | 57 | 83.8% |
| 3626 | 58 | 58 | 55 | 94.8% |
| 3633 | 82 | 82 | 65 | 79.3% |
| 3639 | 948 | 948 | 883 | 93.1% |
| 3658 | 10 | 10 | 7 | 70.0% |
| 3659 | 93 | 93 | 78 | 83.9% |
| 3687 | 145 | 145 | 130 | 89.7% |
| 3702 | 796 | 796 | 764 | 96.0% |
| 3728 | 3 | 3 | 3 | 100.0% |
| 3769 | 748 | 748 | 720 | 96.3% |
| 3794 | 290 | 290 | 7 | 2.4% |
| 3826 | 157 | 157 | 85 | 54.1% |
| 3847 | 909 | 909 | 633 | 69.6% |
| 3862 | 11 | 11 | 7 | 63.6% |
| 3879 | 236 | 236 | 1 | 0.4% |
| 3904 | 966 | 966 | 934 | 96.7% |
| 3932 | 87 | 87 | 75 | 86.2% |
| 3942 | 131 | 131 | 81 | 61.8% |
| 3959 | 71 | 71 | 39 | 54.9% |
| 3969 | 56 | 56 | 48 | 85.7% |
| 3972 | 183 | 183 | 179 | 97.8% |
| 3973 | 254 | 254 | 239 | 94.1% |
| 3975 | 35 | 35 | 34 | 97.1% |
| 3976 | 384 | 384 | 363 | 94.5% |
| 3977 | 892 | 892 | 9 | 1.0% |
| 3978 | 515 | 515 | 143 | 27.8% |
| 3979 | 530 | 530 | 477 | 90.0% |
| 3980 | 267 | 267 | 250 | 93.6% |
| 3981 | 1933 | 1933 | 1824 | 94.4% |
| 3982 | 428 | 428 | 409 | 95.6% |
| 3983 | 293 | 293 | 284 | 96.9% |
| 3984 | 54 | 54 | 45 | 83.3% |
| 3985 | 47 | 47 | 47 | 100.0% |
| 3998 | 104 | 104 | 96 | 92.3% |
| 4014 | 134 | 134 | 118 | 88.1% |
| 4018 | 107 | 107 | 95 | 88.8% |
| 4035 | 138 | 138 | 31 | 22.5% |
| 4039 | 106 | 106 | 56 | 52.8% |
| 4068 | 20 | 20 | 15 | 75.0% |
| 4088 | 222 | 222 | 200 | 90.1% |
| 4122 | 81 | 81 | 78 | 96.3% |
| 4126 | 70 | 70 | 62 | 88.6% |
| 4220 | 131 | 131 | 111 | 84.7% |
| 4221 | 77 | 77 | 70 | 90.9% |
| 4235 | 100 | 100 | 73 | 73.0% |
| 7685 | 151 | 151 | 150 | 99.3% |
| 7718 | 80 | 80 | 68 | 85.0% |
| 7722 | 76 | 76 | 66 | 86.8% |
| 7728 | 53 | 53 | 53 | 100.0% |
| 7734 | 255 | 255 | 244 | 95.7% |
| 7738 | 865 | 865 | 816 | 94.3% |
| 7758 | 28 | 28 | 27 | 96.4% |
| 7765 | 399 | 399 | 370 | 92.7% |
| 7766 | 512 | 512 | 498 | 97.3% |
| 7772 | 435 | 435 | 327 | 75.2% |
| 7780 | 6 | 6 | 5 | 83.3% |
| 7782 | 18 | 18 | 12 | 66.7% |
| 7785 | 283 | 283 | 270 | 95.4% |
| 7802 | 545 | 545 | 517 | 94.9% |
| 7807 | 149 | 149 | 10 | 6.7% |
| 7821 | 71 | 71 | 66 | 93.0% |
| 7833 | 135 | 135 | 1 | 0.7% |
| 7834 | 150 | 150 | 121 | 80.7% |
| 7845 | 219 | 219 | 173 | 79.0% |
| 7857 | 7 | 7 | 3 | 42.9% |
| 7878 | 46 | 46 | 37 | 80.4% |
| 7885 | 438 | 438 | 426 | 97.3% |
| 7886 | 113 | 113 | 113 | 100.0% |
| 7888 | 402 | 402 | 383 | 95.3% |
| 7892 | 151 | 151 | 89 | 58.9% |
| 7910 | 1 | 1 | 1 | 100.0% |
| 7911 | 28 | 28 | 25 | 89.3% |
| 7913 | 71 | 71 | 21 | 29.6% |
| 7919 | 29 | 29 | 29 | 100.0% |
| 7920 | 73 | 73 | 58 | 79.5% |
| 7929 | 537 | 537 | 521 | 97.0% |
| 7931 | 410 | 410 | 370 | 90.2% |
| 7942 | 734 | 734 | 674 | 91.8% |
| 7955 | 131 | 131 | 117 | 89.3% |
| 7964 | 43 | 43 | 0 | 0.0% |
| 7985 | 62 | 62 | 62 | 100.0% |
| 7997 | 234 | 234 | 224 | 95.7% |
| 7998 | 34 | 34 | 33 | 97.1% |
| 8000 | 833 | 833 | 776 | 93.2% |
| 8005 | 275 | 275 | 254 | 92.4% |
| 8018 | 210 | 210 | 193 | 91.9% |
| 8027 | 64 | 64 | 2 | 3.1% |
| 8029 | 337 | 337 | 323 | 95.9% |
| 8030 | 45 | 45 | 34 | 75.6% |
| 8063 | 49 | 49 | 41 | 83.7% |
| 8067 | 335 | 335 | 297 | 88.7% |
| 8079 | 216 | 216 | 44 | 20.4% |
| 8102 | 71 | 71 | 70 | 98.6% |
| 8111 | 125 | 125 | 104 | 83.2% |
| 8119 | 350 | 350 | 264 | 75.4% |
| 8129 | 228 | 228 | 163 | 71.5% |
| 8130 | 170 | 170 | 145 | 85.3% |
| 8131 | 716 | 716 | 691 | 96.5% |
| 8132 | 646 | 646 | 612 | 94.7% |
| 8133 | 837 | 837 | 673 | 80.4% |
| 8134 | 501 | 501 | 428 | 85.4% |
| 8135 | 447 | 447 | 288 | 64.4% |
| 8136 | 236 | 236 | 229 | 97.0% |
| 8142 | 86 | 86 | 79 | 91.9% |
| 8143 | 108 | 108 | 99 | 91.7% |
| 8149 | 1 | 1 | 0 | 0.0% |
| 8160 | 674 | 674 | 608 | 90.2% |
| 8163 | 56 | 56 | 6 | 10.7% |
| 8166 | 99 | 99 | 72 | 72.7% |
| 8167 | 30 | 30 | 11 | 36.7% |
| 8180 | 91 | 91 | 84 | 92.3% |
| 8181 | 91 | 91 | 88 | 96.7% |
| 8199 | 1410 | 1410 | 1351 | 95.8% |
| 8228 | 352 | 352 | 294 | 83.5% |
| 8229 | 83 | 83 | 78 | 94.0% |
| 8242 | 4937 | 4937 | 4739 | 96.0% |
| 8260 | 60 | 60 | 44 | 73.3% |
| 8261 | 215 | 215 | 156 | 72.6% |
| 8262 | 69 | 69 | 1 | 1.5% |
| 8263 | 515 | 515 | 467 | 90.7% |
| 8265 | 888 | 888 | 851 | 95.8% |
| 8277 | 208 | 208 | 206 | 99.0% |
| 8282 | 20 | 20 | 8 | 40.0% |
| 8284 | 25 | 25 | 23 | 92.0% |
| 8288 | 8 | 8 | 6 | 75.0% |
| 8294 | 115 | 115 | 115 | 100.0% |
| 8295 | 83 | 83 | 83 | 100.0% |
| 8300 | 2 | 2 | 1 | 50.0% |
| 8301 | 6 | 6 | 3 | 50.0% |
| 8302 | 7 | 7 | 0 | 0.0% |
| 8305 | 14 | 14 | 13 | 92.9% |
| 8308 | 5 | 5 | 3 | 60.0% |
| 8313 | 347 | 347 | 343 | 98.9% |
| 8320 | 21 | 21 | 20 | 95.2% |
| 8323 | 191 | 191 | 191 | 100.0% |
| 8330 | 1 | 1 | 1 | 100.0% |
| 8332 | 8 | 8 | 7 | 87.5% |
| 8334 | 2 | 2 | 2 | 100.0% |
| 8355 | 220 | 220 | 207 | 94.1% |
| 8369 | 242 | 242 | 20 | 8.3% |
| 8373 | 210 | 210 | 205 | 97.6% |
| 8387 | 317 | 317 | 278 | 87.7% |
| 8396 | 744 | 744 | 373 | 50.1% |
| 8397 | 345 | 345 | 295 | 85.5% |
| 8399 | 44 | 44 | 44 | 100.0% |
| 8401 | 114 | 114 | 111 | 97.4% |
| 8403 | 429 | 429 | 406 | 94.6% |
| 8405 | 70 | 70 | 64 | 91.4% |
| 8407 | 143 | 143 | 114 | 79.7% |
| 8411 | 882 | 882 | 861 | 97.6% |
| 8412 | 7 | 7 | 0 | 0.0% |
| 8414 | 36 | 36 | 0 | 0.0% |
| 8415 | 12 | 12 | 10 | 83.3% |
| 8419 | 255 | 255 | 213 | 83.5% |
| 8421 | 161 | 161 | 157 | 97.5% |
| 8425 | 43 | 43 | 31 | 72.1% |
| 8426 | 156 | 156 | 122 | 78.2% |
| 8427 | 49 | 49 | 49 | 100.0% |
| 8430 | 18 | 18 | 13 | 72.2% |
| 8432 | 15 | 15 | 15 | 100.0% |
| 8438 | 24 | 24 | 1 | 4.2% |
| 8441 | 28 | 28 | 19 | 67.9% |
| 8504 | 11 | 11 | 11 | 100.0% |
| 8506 | 2865 | 2865 | 59 | 2.1% |
| 8507 | 331 | 331 | 300 | 90.6% |
| 8508 | 150 | 150 | 2 | 1.3% |
| 8510 | 1419 | 1419 | 127 | 9.0% |
| 8511 | 737 | 737 | 70 | 9.5% |
| 8512 | 603 | 603 | 486 | 80.6% |
| 8513 | 83 | 83 | 15 | 18.1% |
| 8537 | 109 | 109 | 72 | 66.1% |
| 8538 | 348 | 348 | 195 | 56.0% |
| 8542 | 638 | 638 | 581 | 91.1% |
| 8546 | 113 | 113 | 108 | 95.6% |
| 8550 | 190 | 190 | 189 | 99.5% |
| 8551 | 195 | 195 | 186 | 95.4% |
| 8553 | 30 | 30 | 29 | 96.7% |
| 8559 | 71 | 71 | 70 | 98.6% |
| 8561 | 371 | 371 | 353 | 95.2% |
| 8563 | 71 | 71 | 59 | 83.1% |
| 8566 | 19 | 19 | 16 | 84.2% |
| 8568 | 39 | 39 | 32 | 82.1% |
| 8570 | 9 | 9 | 8 | 88.9% |
| 8571 | 136 | 136 | 118 | 86.8% |
| 8573 | 62 | 62 | 60 | 96.8% |
| 8575 | 94 | 94 | 89 | 94.7% |
| 8577 | 33 | 33 | 12 | 36.4% |
| 8579 | 6 | 6 | 3 | 50.0% |
| 8580 | 244 | 244 | 201 | 82.4% |
| 8598 | 1666 | 1666 | 1599 | 96.0% |
| 8608 | 46 | 46 | 9 | 19.6% |
| 8611 | 68 | 68 | 49 | 72.1% |
| 8618 | 166 | 166 | 7 | 4.2% |
| 8624 | 689 | 689 | 646 | 93.8% |
| 8626 | 13 | 13 | 13 | 100.0% |
| 8632 | 297 | 297 | 155 | 52.2% |
| 8635 | 17 | 17 | 16 | 94.1% |
| 8636 | 5 | 5 | 4 | 80.0% |
| 8638 | 4 | 4 | 4 | 100.0% |
| 8639 | 33 | 33 | 32 | 97.0% |
| 8640 | 9 | 9 | 9 | 100.0% |
| 8641 | 10 | 10 | 10 | 100.0% |
| 8644 | 6 | 6 | 5 | 83.3% |
| 8645 | 4 | 4 | 4 | 100.0% |
| 8650 | 152 | 152 | 144 | 94.7% |
| 8651 | 191 | 191 | 25 | 13.1% |
| 8653 | 2 | 2 | 2 | 100.0% |

Summary statistics for proportion of patients prescribed ART across providers

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Year | N | Mean | SD | Min. | 10th percentile | Lower quartile | Median | Upper quartile | 90th percentile | Max. |
| 2010 | 846 | 65.9% | 27.5% | 0.0% | 17.8% | 51.9% | 76.5% | 86.1% | 91.2% | 100.0% |
| 2011 | 811 | 70.1% | 26.4% | 0.0% | 26.1% | 60.1% | 79.8% | 88.7% | 93.2% | 100.0% |
| 2012 | 816 | 73.4% | 25.4% | 0.0% | 31.7% | 63.5% | 83.8% | 90.7% | 94.7% | 100.0% |
| 2013 | 823 | 77.5% | 24.1% | 0.0% | 42.9% | 71.4% | 86.5% | 93.4% | 96.4% | 100.0% |
| 2014 | 813 | 78.0% | 28.0% | 0.0% | 29.6% | 73.5% | 90.0% | 95.9% | 98.3% | 100.0% |

*Data source*

The data source for this analysis is the Ryan White HIV/AIDS Program Services Report (RSR). The Ryan White HIV/AIDS Program (RWHAP) supports a comprehensive system of care that ensures ongoing access to high quality HIV care, treatment, and support services. The RSR dataset is the HRSA HIV/AIDS Bureau’s primary source of annual, provider- and client-level data collected from more than 2,000 funded grant recipients and subrecipients. Since 2010, RSR data have been used to assess the numbers and types of clients receiving services and their HIV-related outcomes. The analysis includes data reported to the RSR for clients living with HIV served by the RWHAP during calendar years 2010 through 2014. The data are inclusive of all RWHAP providers delivering outpatient ambulatory medical care to clients living with HIV.

Summary of measured entities (providers) and patients, by year

|  |  |  |
| --- | --- | --- |
| Year | Providers (N) | Patients (N) |
| 2010 | 846 | 324,455 |
| 2011 | 811 | 327,744 |
| 2012 | 816 | 335,408 |
| 2013 | 823 | 327,618 |
| 2014 | 813 | 316,087 |

1b.3. If no or limited performance data on the measure as specified is reported in 1b2,

N/A

1b.4. Provide disparities data from the measure as specified (current and over time) by population group, e.g., by race/ethnicity, gender, age, insurance status, socioeconomic status, and/or disability. (This is required for maintenance of endorsement. Describe the data source including number of measured entities; number of patients; dates of data; if a sample, characteristics of the entities included.) For measures that show high levels of performance, i.e., “topped out”, disparities data may demonstrate an opportunity for improvement/gap in care for certain sub‐populations. This information also will be used to address the sub‐criterion on improvement (4b) under Usability and Use.

*Performance scores*

Client-level performance scores for viral load suppression for 2010-2014 (overall and by population group) are presented below.

|  |  |  |
| --- | --- | --- |
| **Patients prescribed ART by select characteristics and key NHAS populations** |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| *ART overall* |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  | 2010 | | | 2011 | | | 2012 | | | 2013 | | | 2014 | | |
|  | N | n | % | N | n | % | N | n | % | N | n | % | N | n | % |
| Total number of patients | 324455 | ─ | ─ | 327744 | ─ | ─ | 335408 | ─ | ─ | 327618 | ─ | ─ | 316,087 | ─ | ─ |
| Patients with ≥1 medical visits during measurement year | 324455 | 324455 | 100.0 | 327744 | 327744 | 100.0 | 335408 | 335408 | 100.0 | 327618 | 327618 | 100.0 | 316,087 | 316,087 | 100.0 |
| Patients prescribed ART | 324455 | 221908 | 68.4 | 327744 | 233132 | 71.1 | 335408 | 249094 | 74.3 | 327618 | 253972 | 77.5 | 316,087 | 245,400 | 77.6 |
| *ART by subgroup* |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  | 2010 | | | 2011 | | | 2012 | | | 2013 | | | 2014 | | |
|  | N | n | % | N | n | % | N | n | % | N | n | % | N | n | % |
| **AGE GROUP** |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| <13 | 3,760 | 1,089 | 28.9 | 3,715 | 1,174 | 31.5 | 3,208 | 979 | 30.4 | 2,756 | 907 | 32.9 | 2,683 | 839 | 30.4 |
| 13–14 | 649 | 453 | 69.0 | 620 | 465 | 74.0 | 479 | 358 | 74.3 | 375 | 298 | 79.3 | 354 | 276 | 76.0 |
| 15–19 | 3,797 | 2,227 | 57.6 | 3,654 | 2,431 | 65.1 | 3,183 | 2,176 | 67.0 | 2,727 | 1,948 | 69.8 | 2,260 | 1,674 | 62.8 |
| 20–24 | 14,458 | 7,490 | 50.0 | 15,152 | 8,539 | 54.4 | 16,309 | 9,979 | 59.3 | 16,327 | 10,940 | 65.1 | 13,609 | 9,697 | 60.2 |
| 25–29 | 22,427 | 13,025 | 55.9 | 23,583 | 14,652 | 59.9 | 25,537 | 16,719 | 63.5 | 26,726 | 18,960 | 68.9 | 25,794 | 18,597 | 65.1 |
| 30–34 | 29,236 | 18,587 | 61.5 | 29,820 | 19,926 | 64.8 | 30,780 | 21,529 | 67.8 | 30,678 | 22,756 | 72.0 | 29,007 | 21,326 | 68.9 |
| 35–39 | 36,085 | 24,742 | 66.5 | 34,349 | 24,241 | 68.7 | 33,865 | 24,690 | 71.0 | 32,803 | 25,025 | 74.3 | 31,546 | 23,690 | 71.6 |
| 40–44 | 52,256 | 36,699 | 68.4 | 49,094 | 35,686 | 71.0 | 46,792 | 35,264 | 73.8 | 42,538 | 33,494 | 77.0 | 38,578 | 29,771 | 74.6 |
| 45–49 | 62,308 | 45,010 | 70.6 | 61,209 | 45,558 | 73.0 | 60,116 | 46,612 | 76.2 | 55,316 | 44,354 | 78.8 | 50,272 | 39,933 | 77.5 |
| 50–54 | 48,143 | 34,817 | 70.9 | 50,159 | 37,663 | 73.8 | 52,727 | 41,272 | 77.1 | 52,786 | 42,702 | 79.7 | 52,992 | 42,858 | 79.3 |
| 55–59 | 28,966 | 21,114 | 71.5 | 31,569 | 23,842 | 74.3 | 34,438 | 27,216 | 78.0 | 35,019 | 28,521 | 80.4 | 36,103 | 29,446 | 80.0 |
| 60–64 | 13,910 | 10,376 | 73.3 | 15,679 | 11,959 | 75.2 | 17,567 | 13,945 | 78.5 | 18,497 | 15,010 | 80.2 | 20,237 | 16,702 | 81.2 |
| ≥65 | 8,378 | 6,207 | 72.9 | 9,139 | 6,994 | 75.7 | 10,392 | 8,345 | 79.5 | 11,067 | 9,054 | 81.1 | 12,539 | 10,491 | 82.3 |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| **RACE/ETHNICITY** |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| American Indian/Alaska Native | 1,477 | 1,054 | 69.2 | 1,360 | 975 | 70.0 | 1,366 | 1,007 | 71.8 | 1,422 | 1,101 | 76.1 | 1,256 | 1,019 | 78.0 |
| Asian | 3,371 | 2,275 | 65.5 | 3,584 | 2,441 | 66.0 | 4,010 | 2,866 | 69.7 | 3,968 | 3,023 | 74.4 | 3,862 | 2,979 | 72.4 |
| Black/African American | 150,933 | 100,645 | 64.9 | 154,085 | 106,917 | 67.8 | 156,159 | 114,257 | 71.5 | 152,593 | 115,487 | 74.1 | 145,763 | 113,551 | 74.3 |
| Hispanic/Latino | 73,953 | 51,030 | 67.3 | 74,092 | 53,896 | 71.2 | 77,909 | 59,585 | 74.9 | 78,943 | 63,302 | 78.5 | 78,104 | 59,060 | 72.6 |
| Native Hawaiian/Pacific Islander | 629 | 415 | 64.5 | 706 | 494 | 68.0 | 587 | 408 | 68.1 | 515 | 396 | 75.1 | 437 | 328 | 71.9 |
| White | 85,523 | 61,675 | 70.6 | 83,998 | 61,930 | 72.3 | 85,700 | 65,106 | 74.7 | 81,594 | 64,413 | 77.6 | 77,862 | 61,886 | 76.5 |
| Multiple races | 3,359 | 2,479 | 72.0 | 3,872 | 2,891 | 73.0 | 4,577 | 3,435 | 73.9 | 5,249 | 4,174 | 78.2 | 6,213 | 5,139 | 79.3 |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| **GENDER** |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Male | 224,388 | 154,000 | 66.8 | 227,661 | 162,001 | 69.4 | 236,098 | 175,038 | 72.5 | 230,304 | 178,007 | 75.6 | 221,711 | 170,992 | 73.5 |
| Female | 97,655 | 66,271 | 66.4 | 97,411 | 69,198 | 69.8 | 96,351 | 71,838 | 73.3 | 94,446 | 73,740 | 76.8 | 91,167 | 72,020 | 76.4 |
| Transgender | 2,349 | 1,599 | 66.6 | 2,624 | 1,899 | 70.9 | 2,916 | 2,188 | 73.5 | 2,833 | 2,202 | 76.1 | 3,019 | 2,244 | 70.6 |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| **TRANSMISSION RISK** |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| **Male client** |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Male-to-male sexual contact | 120,047 | 83,956 | 68.2 | 123,216 | 88,469 | 70.1 | 132,362 | 98,703 | 73.0 | 133,086 | 103,818 | 76.4 | 130,575 | 100,726 | 73.1 |
| Injection drug use | 17,880 | 13,468 | 73.7 | 17,206 | 13,437 | 76.9 | 16,158 | 12,831 | 78.3 | 15,933 | 12,797 | 79.2 | 14,241 | 11,936 | 82.5 |
| Male-to-male sexual contact   and injection drug use | 7,265 | 5,481 | 73.8 | 7,049 | 5,449 | 75.8 | 7,273 | 5,659 | 76.5 | 6,374 | 5,109 | 79.0 | 6,688 | 5,270 | 76.3 |
| Heterosexual contact | 50,240 | 35,577 | 68.3 | 52,079 | 37,597 | 70.1 | 53,879 | 41,198 | 74.4 | 53,265 | 42,316 | 77.3 | 52,574 | 41,827 | 76.2 |
| Perinatal infection | 3,934 | 2,073 | 52.4 | 4,077 | 2,377 | 58.0 | 3,755 | 2,233 | 58.9 | 3,608 | 2,307 | 63.5 | 3,622 | 2,265 | 61.5 |
| Other | 1,253 | 988 | 78.9 | 1,243 | 952 | 76.6 | 1,327 | 1,057 | 79.7 | 1,394 | 1,034 | 74.2 | 1,209 | 972 | 80.4 |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| **Female client** |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Injection drug use | 9678 | 7128 | 72.4 | 9367 | 7198 | 75.9 | 8564 | 6682 | 77.2 | 8649 | 6802 | 77.7 | 7846 | 6570 | 82.1 |
| Heterosexual contact | 71777 | 50457 | 68.8 | 73013 | 52976 | 71.2 | 73988 | 56234 | 74.6 | 73958 | 59120 | 78.6 | 72643 | 58532 | 77.9 |
| Perinatal infection | 4509 | 2477 | 54.7 | 4753 | 2858 | 59.5 | 4363 | 2725 | 62.0 | 4250 | 2833 | 66.3 | 4319 | 2909 | 66.4 |
| Other | 911 | 667 | 73.2 | 895 | 690 | 77.1 | 959 | 732 | 76.3 | 1073 | 781 | 72.8 | 965 | 757 | 78.4 |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| **Transgender client** |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Sexual contact | 1,899 | 1,332 | 68.7 | 2,082 | 1,538 | 72.3 | 2,337 | 1,787 | 74.8 | 2,361 | 1,879 | 77.9 | 2,518 | 1,888 | 71.1 |
| Injection drug use | 40 | 25 | 62.5 | 31 | 21 | 65.6 | 35 | 31 | 86.1 | 36 | 31 | 86.1 | 35 | 32 | 86.5 |
| Sexual contact and   injection drug use | 158 | 111 | 69.4 | 168 | 137 | 80.6 | 177 | 147 | 82.1 | 138 | 118 | 84.3 | 161 | 133 | 81.1 |
| Perinatal infection | 5 | 2 | 40.0 | 5 | 2 | 40.0 | 2 | 2 | 100.0 | 3 | 3 | 75.0 | 10 | 7 | 70.0 |
| Other | 6 | 6 | 100.0 | 5 | 3 | 60.0 | 8 | 6 | 75.0 | 9 | 6 | 66.7 | 8 | 6 | 75.0 |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| **HEALTH CARE COVERAGE** |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Private only | 35,620 | 25,012 | 68.9 | 37,770 | 27,430 | 71.5 | 40,585 | 29,672 | 72.1 | 37,842 | 29,025 | 75.4 | ─ | ─ | ─ |
| Medicare only | 23,675 | 17,841 | 74.3 | 24,587 | 18,748 | 75.5 | 23,832 | 19,263 | 80.0 | 23,203 | 18,623 | 79.6 | ─ | ─ | ─ |
| Medicaid only | 74,878 | 52,599 | 68.5 | 77,690 | 57,584 | 72.7 | 74,114 | 57,361 | 75.9 | 71,917 | 57,882 | 79.0 | ─ | ─ | ─ |
| Other public | 22,622 | 17,227 | 74.2 | 21,143 | 17,146 | 78.7 | 28,265 | 23,524 | 81.2 | 28,792 | 23,813 | 80.5 | ─ | ─ | ─ |
| Other private | 12,376 | 8,430 | 66.0 | 10,262 | 7,731 | 73.0 | 6,513 | 4,945 | 73.8 | 3,961 | 3,056 | 75.6 | ─ | ─ | ─ |
| No coverage | 89,445 | 56,319 | 60.9 | 103,033 | 66,254 | 62.4 | 107,568 | 71,918 | 65.1 | 106,007 | 76,585 | 70.3 | ─ | ─ | ─ |
| Multiple coverages | 36,014 | 28,400 | 77.5 | 37,973 | 30,981 | 80.4 | 45,317 | 37,122 | 80.8 | 48,347 | 40,507 | 82.8 | ─ | ─ | ─ |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Private employer | ─ | ─ | ─ | ─ | ─ | ─ | ─ | ─ | ─ | ─ | ─ | ─ | 18,366 | 15,888 | 82.2 |
| Private individual | ─ | ─ | ─ | ─ | ─ | ─ | ─ | ─ | ─ | ─ | ─ | ─ | 16,745 | 13,824 | 79.2 |
| Medicare | ─ | ─ | ─ | ─ | ─ | ─ | ─ | ─ | ─ | ─ | ─ | ─ | 26,653 | 22,312 | 82.6 |
| Medicaid | ─ | ─ | ─ | ─ | ─ | ─ | ─ | ─ | ─ | ─ | ─ | ─ | 96,909 | 77,246 | 76.4 |
| Medicare and Medicaid | ─ | ─ | ─ | ─ | ─ | ─ | ─ | ─ | ─ | ─ | ─ | ─ | 20,289 | 17,638 | 86.0 |
| Veterans Administration | ─ | ─ | ─ | ─ | ─ | ─ | ─ | ─ | ─ | ─ | ─ | ─ | 459 | 395 | 82.5 |
| Indian Health Service | ─ | ─ | ─ | ─ | ─ | ─ | ─ | ─ | ─ | ─ | ─ | ─ | 71 | 54 | 71.1 |
| Other plan | ─ | ─ | ─ | ─ | ─ | ─ | ─ | ─ | ─ | ─ | ─ | ─ | 12,436 | 6,489 | 50.6 |
| No coverage | ─ | ─ | ─ | ─ | ─ | ─ | ─ | ─ | ─ | ─ | ─ | ─ | 92,801 | 67,980 | 68.6 |
| Multiple coverages | ─ | ─ | ─ | ─ | ─ | ─ | ─ | ─ | ─ | ─ | ─ | ─ | 25,236 | 19,796 | 76.6 |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| **PROVIDER TYPE** |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Hospital or university-based clinic | 145,727 | 107,562 | 71.9 | 153,052 | 116,407 | 74.2 | 153,179 | 122,115 | 77.9 | 145,773 | 119,168 | 80.0 | 143,008 | 122,979 | 82.6 |
| Community based organization | 111,315 | 77,873 | 68.2 | 109,419 | 81,312 | 72.7 | 113,318 | 87,000 | 75.3 | 115,540 | 92,106 | 78.2 | 103,675 | 72,660 | 66.8 |
| Health department | 52,797 | 25,642 | 47.6 | 52,964 | 25,670 | 47.6 | 56,309 | 30,242 | 52.9 | 53,925 | 32,196 | 58.7 | 56,600 | 38,581 | 65.5 |
| Other | 14,616 | 10,831 | 71.8 | 12,309 | 9,743 | 77.8 | 12,602 | 9,737 | 75.4 | 12,380 | 10,502 | 82.7 | 12,804 | 11,180 | 82.3 |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| **NHAS POPULATIONS** |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Black women | 59,569 | 39,782 | 65.3 | 59,727 | 41,887 | 68.8 | 58,549 | 43,202 | 72.4 | 57,014 | 43,737 | 75.4 | 54,158 | 42,564 | 75.9 |
| Black men | 90,116 | 60,061 | 64.6 | 93,067 | 64,148 | 67.1 | 96,086 | 69,943 | 71.0 | 94,094 | 70,633 | 73.3 | 89,907 | 69,717 | 73.4 |
| Hispanic women | 19,529 | 13,756 | 69.1 | 19,460 | 14,432 | 73.0 | 19,516 | 15,187 | 76.7 | 19,742 | 16,165 | 80.7 | 19,662 | 15,686 | 77.8 |
| Hispanic men | 53,672 | 36,731 | 66.6 | 53,795 | 38,833 | 70.4 | 57,473 | 43,670 | 74.3 | 58,290 | 46,398 | 77.8 | 57,476 | 42,681 | 70.9 |
| Youth (13-24 years) | 3,768 | 1,956 | 50.5 | 3,742 | 2,121 | 55.1 | 3,900 | 2,238 | 56.1 | 3,715 | 2,513 | 66.2 | 2,911 | 2,087 | 59.4 |
| Transgender women | 2,175 | 1,523 | 68.5 | 2,428 | 1,803 | 72.8 | 2,657 | 2,058 | 75.8 | 2,584 | 2,048 | 77.6 | 2,801 | 2,099 | 72.0 |

*Data source*

The data source for this analysis is the Ryan White HIV/AIDS Program Services Report (RSR). The Ryan White HIV/AIDS Program (RWHAP) supports a comprehensive system of care that ensures ongoing access to high quality HIV care, treatment, and support services. The RSR dataset is the HRSA HIV/AIDS Bureau’s primary source of annual, provider- and client-level data collected from more than 2,000 funded grant recipients and subrecipients. Since 2010, RSR data have been used to assess the numbers and types of clients receiving services and their HIV-related outcomes. The analysis includes data reported to the RSR for clients living with HIV served by the RWHAP during calendar years 2010 through 2014. The data are inclusive of all RWHAP providers delivering outpatient ambulatory medical care to clients living with HIV.

Summary of measured entities (providers) and patients, by year

|  |  |  |
| --- | --- | --- |
| Year | Providers (N) | Patients (N) |
| 2010 | 846 | 324,455 |
| 2011 | 811 | 327,744 |
| 2012 | 816 | 335,408 |
| 2013 | 823 | 327,618 |
| 2014 | 813 | 316,087 |

1b.5. If no or limited data on disparities from the measure as specified is reported in 1b.4,

N/A

Scientific Acceptability

Testing Attachment

2. Attach measure testing form (Click to here to download the [Measure Testing Form Template](http://nqf.qualityforum.dev.win.dotnet.panth.com/docs/NQF_testing_attachment_FINAL_2016.aspx) OR the Composite Measure Testing Form.)

2.1. For maintenance of endorsement:

Reliability testing:

Yes, information in the attached testing form is all new.

2.2. For maintenance of endorsement:

Has additional empirical validity testing of the measure score been conducted? If yes, please provide results in the Testing attachment. (Do not remove prior testing information – include date of new information in red.)

No

2.3. For maintenance of endorsement:

Risk adjustment:

No ‐ This measure is not risk‐adjusted.

Feasibility

Data Elements Generated as Byproduct of Care Processes ([Measure evaluation criterion 3a](http://nqf.qualityforum.dev.win.dotnet.panth.com/#3a))

3a.1. How are the data elements needed to compute measure scores generated? (Check all that apply)

Data used in the measure are:

Generated "or collected" by and used by healthcare personnel during the provision of care (e.g., blood pressure, lab value, diagnosis, "depression score")

Abstracted from a record by someone other than person obtaining original information (e.g., chart abstraction for quality measure or registry)

Electronic Sources ([Measure evaluation criterion 3b](http://nqf.qualityforum.dev.win.dotnet.panth.com/#3b))

3b.1. To what extent are the specified data elements available electronically in defined fields ( *i.e., data* *elements that are needed to compute the performance measure score are in defined, computer‐readable fields*)Update this field for maintenance of endorsement.

All data elements are in defined fields in electronic health records (EHRs)

3b.2. If ALL the data elements needed to compute the performance measure score are not from electronic sources, specify a credible, near‐term path to electronic capture, OR provide a rationale for using other than electronic sources. For maintenance of endorsement, if this measure is not an eMeasure (eCQM), please describe any efforts to develop an eMeasure (eCQM).

For this measure, we are also presenting an e-measure.

3b.3. If this is an eMeasure, provide a summary of the feasibility assessment in an attached file or make available at a measure‐specific URL. Please also complete and attach the NQF Feasibility Score Card.

N/A

Data Collection Strategy ([Measure evaluation criterion 3c](http://nqf.qualityforum.dev.win.dotnet.panth.com/#3c))

3c.1. Required for maintenance of endorsement. Describe difficulties (as a result of testing and/or operational use of the measure) regarding data collection, availability of data, missing data, timing and frequency of data collection, sampling, patient confidentiality, time and cost of data collection, other feasibility/implementation issues.

Data collection and availability: The data used for testing and operational use of this measure are readily available within patient health records and provided annually to the Ryan White HIV/AIDS Program through the reporting of the Ryan White Service Report (approved by the Office of Management and Budget 0915-0323).

Missing data: A full analysis of missing data is provided in this submission.

Time and frequency of data collection: As noted previously, all variables to calculate this measure are contained in a patient health record in a structured field. These data are routinely collected in the provision of care to people living with HIV. Because the availability of data, sampling is not performed.

Patient confidentiality: The data used in the testing of this measure are deidentified/striped of personally identifiable information prior to submitting.

3c.2. Describe any fees, licensing, or other requirements to use any aspect of the measure as specified (e.g., value/code set, risk model, programming code, algorithm)?

No fees, licensing, or other requirements to use any aspect of the measure.

Usability and Use

4.1. Current and Planned Use *(check all the current and planned uses; for any current uses that are checked,* *provide a program name and URL for the specific program)*

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | Intended Use | | | Specific | | | Current | | For current use, provide Program Name and URL |  | |
|  |  | | |  | | |  | |  |  | |
|  | |  |  | |  |  | | | | |
|  | |  | Plan for | |  | Use | |  | | |
|  | |  | Use | |  |  | |  | | |
|  | |  |  | |  |  | |  | | |
|  | | a. Public Reporting | X | |  | X | | Ryan White HIV/AIDS Program \  https://hab.hrsa.gov/clinical-quality-management/performance-measure-portfolio | | |
|  | |  |  | |  |  | |  | | |
|  | | b. Public Health/Disease Surveillance |  | |  | X | | National HIV/AIDS Strategy  https://www.aids.gov/federal-resources/national-hiv-aids-strategy/nhas-update.pdf | | |
|  | |  |  | |  |  | |  | | |
|  | | c. Payment Program | X | |  | X | | Physician Quality Report System and Merit-Based Incentive Payment System  https://www.cms.gov/Medicare/Quality-Initiatives-Patient-Assessment-Instruments/PQRS/index.html?redirect=/pqri | | |
|  | |  |  | |  |  | |  | | |
|  | | d. Regulatory and Accreditation Programs |  | |  |  | |  | | |
|  | |  |  | |  |  | |  | | |
|  | | e. Professional Certification or Recognition |  | |  |  | |  | | |
|  | | Program |  | |  |  | |  | | |
|  | |  |  | |  |  | |  | | |
|  | | f. Quality Improvement with Benchmarking |  | |  |  | |  | | |
|  | | (external benchmarking to multiple |  | |  |  | | National HIV/AIDS Strategy | | |
|  | | organizations) |  | |  |  | |  | | |
|  | |  |  | |  |  | |  | | |
|  | | g. Quality Improvement (Internal to the specific |  | |  |  | | Ryan White HIV/AIDS Program | | |
|  | | organization) |  | |  |  | |  | | |
|  | |  |  | |  |  | |  | | |

Accountability/Transparency ([measure evaluation criterion 4a](http://nqf.qualityforum.dev.win.dotnet.panth.com/#4a))

4a.1. For each CURRENT use, checked above (update for maintenance of endorsement), provide:

Ryan White HIV/AIDS Program

Sponsor: Federal government

Geographic area: Nationwide

Accountable entities: Approximately 600 Ryan White HIV/AIDS Program grant recipients and their providers

Patients: Approximately 316,000 patients

Physician Quality Report System and Value Based Modifier

Sponsor: Federal government

Geographic area: Nationwide

Accountable entities: Physicians and practitioners

Patients: Unknown

Merit-Based Incentive Payment System

Sponsor: Federal government

Geographic area: Nationwide

Accountable entities: Physicians, Physician Assistant, Nurse Practitioner, and Clinical Nurse Specialist

Patients: Unknown

National HIV/AIDS Strategy

Sponsor: Federal government

Geographic area: Nationwide

Accountable entities: Federal agencies and service providers

Patients: All people living with HIV in the United States



4a.2. If not currently publicly reported OR used in at least one other accountability application (e.g., payment program, certification, licensing) what are the reasons? (e.g.*, Do policies or actions of the* *developer/steward or accountable entities restrict access to performance results or impede implementation?*)

N/A

4a.3. If not currently publicly reported OR used in at least one other accountability application, provide a credible plan for implementation within the expected timeframes ‐‐ any accountability application within 3 years and publicly reported within 6 years of initial endorsement.

N/A

Improvement ([measure evaluation criterion 4b](http://nqf.qualityforum.dev.win.dotnet.panth.com/#4b))

4b. Refer to data provided in 1b but do not repeat here. Discuss any progress on improvement (trends in performance results, number and percentage of people receiving high‐quality healthcare; Geographic area and number and percentage of accountable entities and patients included.)

Prescription of HIV antiretroviral therapy has been improving in the United States since the first release of publically available data. The Ryan White HIV/AIDS Program served more than 300,000 unduplicated patients annually between 2010-2014 across 2,000+ grant recipients and subrecipients. The Ryan White HIV/AIDS Program has experienced a 10 + point increase in viral suppression from 65.9% in 2010 to 78.0% in 2014. Prescription of HIV antiretroviral therapy has increased across all demographic groups and subpopulations.

Unexpected findings ([measure evaluation criterion 4c](http://nqf.qualityforum.dev.win.dotnet.panth.com/#4c))

4c.1. Please explain any unexpected findings (positive or negative) during implementation of this measure including unintended impacts on patients.

The adoption and use of this measure has continued to spread since the initial development of this measure. This measure has been adopted by Centers for Medicare and Medicaid measurement programs, Department of Health and Human Service Secretary as a one of the core HIV indicators, countless outpatient/ambulatory care settings, and health departments. National learning collaborates have used this measure to focus the improvement efforts of grant recipients and subrecipients. Additionally, prescription of HIV antiretroviral therapy is one of five stages of the HIV care continuum. This measure has become the standard when measuring prescription of HIV antiretroviral therapy.

4c.2. Please explain any unexpected benefits from implementation of this measure.

N/A

Vetting of the measure by those being measured by others

4d1.1. Describe how performance results, data, and assistance with interpretation have been provided to those being

Starting in 2015, Health Resources and Services Administration began releasing December 1st – World AIDS Day – an annual data report (Ryan White HIV/AIDS Program Annual Client-Level Data Report) that contains data similar to those presenting in the report. Building upon the success of the state profiles (<http://hab.hrsa.gov/stateprofiles/>), Health Resources and Services Administration worked diligently to release the annual data report in the same year it was collected (collected in April and released in December of the same year). The report is publically available on the Health Resources and Services Administration website (http://hab.hrsa.gov/data/data-reports) and is released via an accompanying webinar (recorded and archived). A supplemental report exploring data for the eligible metropolitan areas and transitional grant areas and youth/young adults has been released as well as slides sets for fact sheets by program and population, special populations (http://hab.hrsa.gov/publications/hivaids-bureau-fact-sheets), and infographics (contained in fact sheets). Additionally, grant recipient level reports are prepared and disseminated to all Ryan White HIV/AIDS Program grant recipients.

4d1.2. Describe the process(es) involved, including when/how often results were provided, what data were provided, what educational/explanatory efforts were made, etc.

Starting in 2015, Health Resources and Services Administration began releasing December 1st – World AIDS Day – an annual data report (Ryan White HIV/AIDS Program Annual Client-Level Data Report) that contains data similar to those presenting in the report. Building upon the success of the state profiles (<http://hab.hrsa.gov/stateprofiles/>), Health Resources and Services Administration worked diligently to release the annual data report in the same year it was collected (collected in April and released in December of the same year). The report is publically available on the Health Resources and Services Administration website (http://hab.hrsa.gov/data/data-reports) and is released via an accompanying webinar (recorded and archived). A supplemental report exploring data for the eligible metropolitan areas and transitional grant areas and youth/young adults has been released as well as slides sets for fact sheets by program and population, special populations (http://hab.hrsa.gov/publications/hivaids-bureau-fact-sheets), and infographics (contained in fact sheets). Additionally, grant recipient level reports are prepared and disseminated to all Ryan White HIV/AIDS Program grant recipients.

4d2.1. Summarize the feedback on measure performance and implementation from the measured entities and others described in 4d.1.

Antidotal feedback has been received from Ryan White HIV/AIDS Program grant recipients and subrecipients regarding the feasibility and usefulness of the data presented in the Ryan White HIV/AIDS Program Annual Client-Level Data Report. Significant feedback has been provided about the timeliness and expansions of the data release. Grant recipient report using the data for benchmarking their program, setting goals/targets, and gaining a fuller understanding of all aspects of the Ryan White HIV/AIDS Program (i.e. other regions of the country). Grant recipients and subrecipients have also requested additional analyses. Health Resources and Services Administration responded with supplemental reports (Ryan White HIV/AIDS Program Supplemental Client-Level Data Report, Eligible Metropolitan Areas and Transitional Grant Areas; special population reports); slide decks for the overall client population and special populations; grant recipient reports; and infographics – all of which will be updated and released annually. Health Resources and Services Administration plans to release additional analyses and special reports this year based on feedback from Ryan White HIV/AIDS Program grant recipients and subrecipients.

4d2.2. Summarize the feedback obtained from those being measured.

See 4d2.2

4d2.3. Summarize the feedback obtained from other users.

Ryan White HIV/AIDS Program national partners (national organizations that represent grant recipients, subrecipients, and patients) has provided antidotal feedback regarding the timeliness, feasibility, and usability of the release of the Ryan White HIV/AIDS Program Annual Client-Level Data Report, supplemental reports, slide decks, fact sheets, and infographics. The national partners encourage the continued release of the data in all its formats.

4d.3. Describe how the feedback described in 4d.2 has been considered when developing or revising the measure specifications or implementation, including whether the measure was modified and why or why not

During the initial development of the measure, formal feedback was gathered. The measures were modified during the development phase and have not been modified since. A concerted effort was made to develop a measure that would likely stand the test of time from a scientific, clinical, and patient perspective. On an annual basis, the measure is review for clinical relevance, change in scientific acceptability, and consistency with guidelines. This measure has not been modified as a result of the annual reviews. Additionally, this measure is used by a number of measurement programs and strategies. Each of those programs require a separate annual review. No modifications have been made for those programs.

Related and Competing Measures

Relation to Other NQF‐endorsed® Measures ([Measure evaluation criterion 5](http://nqf.qualityforum.dev.win.dotnet.panth.com/#5))

5. Are there related measures (conceptually, either same measure focus or target population) or competing measures (conceptually both the same measure focus and same target population)? If yes, list the NQF # and title of all related and/or competing measures. (Can search and select measures.)

0405 HIV/AIDS: Pneumocystis Jiroveci Pneumonia (PCP) Prophylaxis

0409 HIV/AIDS: Sexually Transmitted Disease Screening for Chlamydia, Gonorrhea, and Syphilis

2079 HIV Medical Visit Frequency

2080 Gap in HIV Medical Visits

2082 HIV Viral Suppression

3211 Prescription of HIV Antiretroviral Therapy

3210 HIV viral suppression

3010 HIV Medical Visit Frequency

3211 Prescription of HIV Antiretroviral Therapy

Harmonization of Related Measures ([Measure evaluation criterion 5a](http://nqf.qualityforum.dev.win.dotnet.panth.com/#5a))

5a.1. If this measure conceptually addresses EITHER the same measure focus OR the same target population as NQF‐endorsed measure(s):

Yes

5a.2. If the measure specifications are not completely harmonized, identify the differences, rationale, and impact on interpretability and data collection burden.

N/A

Competing Measure(s) ([Measure evaluation criterion 5b](http://nqf.qualityforum.dev.win.dotnet.panth.com/#5b))

5b.1. If this measure conceptually addresses both the same measure focus and the same target population as NQF‐ endorsed measure(s):

This measure does not have a competing measure.